|
Originally published In Press as doi:10.1074/jbc.M106458200 on October 22, 2001
J. Biol. Chem., Vol. 277, Issue 2, 1128-1138, January 11, 2002
Characterization of an Acyl-CoA Thioesterase That Functions as a
Major Regulator of Peroxisomal Lipid Metabolism*
Mary C.
Hunt ,
Karianne
Solaas§,
B. Frode
Kase¶, and
Stefan E. H.
Alexson
From the Department of Medical Laboratory Sciences and Technology,
Division of Clinical Chemistry, Karolinska Institutet, Huddinge
University Hospital, SE-141 86 Stockholm, Sweden and the
¶ Department of Pediatric Research, Rikshospitalet, NO-0027
Oslo, Norway
Received for publication, July 10, 2001, and in revised form, September 25, 2001
 |
ABSTRACT |
Peroxisomes function in -oxidation
of very long and long-chain fatty acids, dicarboxylic fatty acids, bile
acid intermediates, prostaglandins, leukotrienes, thromboxanes,
pristanic acid, and xenobiotic carboxylic acids. These lipids are
mainly chain-shortened for excretion as the carboxylic acids or
transported to mitochondria for further metabolism. Several of these
carboxylic acids are slowly oxidized and may therefore sequester
coenzyme A (CoASH). To prevent CoASH sequestration and to facilitate
excretion of chain-shortened carboxylic acids, acyl-CoA thioesterases,
which catalyze the hydrolysis of acyl-CoAs to the free acid and CoASH, may play important roles. Here we have cloned and characterized a
peroxisomal acyl-CoA thioesterase from mouse, named PTE-2 (peroxisomal acyl-CoA thioesterase 2). PTE-2 is ubiquitously expressed and induced
at mRNA level by treatment with the peroxisome proliferator WY-14,643 and fasting. Induction seen by these treatments was dependent
on the peroxisome proliferator-activated receptor . Recombinant PTE-2 showed a broad chain length specificity with acyl-CoAs from short- and medium-, to long-chain acyl-CoAs, and other
substrates including trihydroxycoprostanoyl-CoA,
hydroxymethylglutaryl-CoA, and branched chain acyl-CoAs, all of which
are present in peroxisomes. Highest activities were found with the CoA
esters of primary bile acids choloyl-CoA and chenodeoxycholoyl-CoA as
substrates. PTE-2 activity is inhibited by free CoASH, suggesting that
intraperoxisomal free CoASH levels regulate the activity of this
enzyme. The acyl-CoA specificity of recombinant PTE-2 closely resembles
that of purified mouse liver peroxisomes, suggesting that PTE-2 is the
major acyl-CoA thioesterase in peroxisomes. Addition of recombinant
PTE-2 to incubations containing isolated mouse liver peroxisomes
strongly inhibited bile acid-CoA:amino acid
N-acyltransferase activity, suggesting that this
thioesterase can interfere with CoASH-dependent pathways.
We propose that PTE-2 functions as a key regulator of peroxisomal lipid metabolism.
 |
INTRODUCTION |
Peroxisomes are cellular organelles present in all eukaryotic
cells. They play an indispensable role in the metabolism of a variety
of lipids including very long-chain fatty acids, dicarboxylic fatty
acids, bile acids, prostaglandins, leukotrienes, thromboxanes, pristanic acid, and xenobiotic fatty acids (for review, see Refs. 1 and
2). The peroxisomal -oxidation system contains two sets of enzymes,
one of which is involved in the oxidation of branched chain fatty acids
and intermediates in the hepatic bile acid biosynthetic pathway and
consists of one or two branched-chain acyl-CoA oxidase(s), a
D-specific bifunctional protein and the sterol carrier-like
protein x (SCPx). The second pathway is involved in the oxidation of
very long straight-chain fatty acids, CoA esters of prostaglandins,
leukotrienes, and thromboxanes (prostanoids) and dicarboxylic acids.
This system is composed of a straight-chain acyl-CoA oxidase, an
L-specific bifunctional protein and straight-chain 3-ketoacyl-CoA thiolase. However, these two pathways are not mutually exclusive (1). All enzymes in this latter pathway are induced by
peroxisome proliferators, whereas the enzymes in the former -oxidation pathway are not. Peroxisome proliferators are a group of
structurally diverse compounds including hypolipidemic drugs, which
induce peroxisome proliferation, hepatomegaly, and cause hepatocarcinogenesis in rodent liver. These peroxisome proliferators, together with free fatty acids, act as ligands for the peroxisome proliferator-activated receptor (PPAR )1 (3, 4). The
PPAR is a nuclear receptor that plays a central role in fatty acid
metabolism and induces the expression of many enzymes involved in
peroxisomal and mitochondrial -oxidation and -oxidation of fatty
acids. Targeted disruption of the PPAR gene in mouse has established
a key role for this receptor as a mediator of lipid metabolism (5-8)
and in the adaptive response to fasting (7-10).
Prior to transport into peroxisomes and -oxidation, all substrates
must be activated to their CoA ester, which occurs at different
cellular locations. Long-chain acyl-CoA synthetases are present in
different subcellular membranes (11, 12) and long-chain acyl-CoA
synthetase in the peroxisomal membrane activates very long and
long-chain fatty acids and possibly branched-chain fatty acids to their
CoA esters. Dicarboxylic fatty acids, prostanoids, and di- and
trihydroxycoprostanic acid are activated to their CoA esters in the
endoplasmic reticulum. These CoA esters are then transported into
peroxisomes, possibly via ABC transporters. Peroxisomal -oxidation
of very long and long-chain fatty acyl-CoAs results in chain-shortening
of these esters, and the chain-shortened products can be transported as
carnitine esters to mitochondria for further degradation. However,
peroxisomes appear to have important roles in -oxidation of a number
of xenobiotic carboxylic acids which may only be partially metabolized
in peroxisomes (13, 14). The -oxidation of other CoA esters, such as
prostanoids results in chain-shortening in peroxisomes, which are
subsequently excreted in urine as the free carboxylic acid (for review,
see Ref. 15). Similarly the -oxidation of dicarboxylic acids results in a chain-shortening in peroxisomes with the dicarboxylic acid being
excreted in urine as the free acid or as glycine conjugates. Several of
these carboxylic acids are only slowly -oxidized, implying that
intraperoxisomal CoASH may be sequestered to such an extent that it
becomes limiting. To maintain appropriate CoASH levels and to
facilitate excretion of chain-shortened carboxylic acids, acyl-CoA
thioesterases are likely to play important roles (for review, see Ref.
16). The hydrolysis of CoA esters to the free acids requires the
presence of an acyl-CoA thioesterase, an enzyme that functions to
hydrolyze CoA esters to the free acid and CoASH. To date, however, the
specific thioesterase(s) active on CoA esters of prostanoids or
dicarboxylic acids have not been identified.
Another important reaction that occurs in liver peroxisomes is the
formation of bile acids. The primary bile acids, cholic acid and
chenodeoxycholic acid, are formed by a number of enzymatic modifications of the cholesterol backbone by P-450 enzymes. The di- or
trihydroxycoprostanoyl-CoA (DHCA-CoA or THCA-CoA) formed undergoes a
final -oxidative cleavage of the side chain in peroxisomes with the
release of propionyl-CoA, to form chenodeoxycholoyl-CoA and
choloyl-CoA, respectively (17, 18). The peroxisomal bile acid-CoA:amino
acid N-acyltransferase (BAAT) then catalyzes the conjugation
of the CoA-activated bile acid to taurine or glycine prior to secretion
from liver into bile. Recently, a multiorganellar bile acid-CoA
thioesterase activity, which hydrolyzes the bile acid-CoA esters to
free bile acids and CoASH, has been characterized in human liver
peroxisomes (19, 20). This bile acid-CoA thioesterase activity
described may compete with the BAAT enzyme for the bile acid-CoA
substrate, thereby influencing intracellular levels of free and
conjugated bile acids.
The existence of selective acyl-CoA thioesterases or a "broad
range" acyl-CoA thioesterase could provide important control points
in the oxidation of many peroxisomal substrates and to regulate
intracellular levels of CoA esters and CoASH. This may be especially
important during times of high -oxidation and fatty acid overload,
to generate free CoASH necessary for fatty acid -oxidation to
proceed. Acyl-CoA thioesterase activity has indeed been shown to be
present in peroxisomes (21-24), and isolated rat brown adipose tissue
peroxisomes contain acyl-CoA thioesterase(s) active on short- and
medium-chain acyl-CoAs, which are inhibited by CoASH (23). Rat liver
peroxisomes showed broad acyl-CoA thioesterase activity on
C2-C22 acyl-CoAs, and one enzyme was partially
purified, which was shown to be most active on myristoyl-CoA (24). To date, several peroxisomal acyl-CoA thioesterases have been cloned from
yeast, mouse, and human. PTE-Ia and -Ib have been cloned from mouse,
which belong to a novel family of Type I acyl-CoA thioesterases, with
related enzymes also in cytosol and mitochondria (25). Acyl-CoA
thioesterases have been identified in yeast and human peroxisomes,
named PTE1 (26). The human homologue of PTE1 was previously identified
as hACTEIII/hTE, a protein that interacted with and activated the HIV-1
Nef protein (27, 28). In the present study we have cloned the mouse
homologue of PTE1/hACTEIII/hTE, which we have named mouse peroxisomal
acyl-CoA thioesterase 2 (PTE-2). We have characterized this enzyme in
detail, to examine its putative function in peroxisomal -oxidation.
Characterization of PTE-2 suggests that it is a major thioesterase with
an array of functions in peroxisomal lipid metabolism.
 |
EXPERIMENTAL PROCEDURES |
Chemicals--
[24-14C]Chenodeoxycholoyl-CoA and
[24-14C]choloyl-CoA (specific activity 48.6 Ci/mol),
trihydroxy-cholestanoyl-CoA, 2-methylstearoyl-CoA, and prostaglandin
F2 -CoA were synthesized by the mixed anhydride procedure
(29) and the former two CoA esters purified by high-pressure liquid
chromatography (HPLC). [24-14C]Chenodeoxycholic acid and
[24-14C]cholic acid were purchased from PerkinElmer Life
Sciences. Optiprep and Maxidens were from Nycomed Pharma AS,
Oslo, Norway. Taurine, chenodeoxycholic acid, cholic acid, all other
acyl-CoAs, and coenzyme A were from Sigma. Prostaglandin
F2 was from Cayman Chemical (Ann Arbor, MI).
Animals and Treatments--
Diurnal variation was investigated
in adult male C57 BL/6 mice (B & K, Sollentuna, Sweden). The mice were
maintained on a normal chow diet and sacrificed at the time points
indicated. The dark periods were between 18.00 and 06.00 h. All other
treatments were carried out on 10- to 12-week-old male wild-type or
PPAR -null mice on a pure Sv/129 genetic background (derived from the
original colony of mixed background mice) (5). These animals were
housed in a temperature- and light-controlled environment. In fasting experiments, mice were maintained on a normal chow diet (R36 Lactamin, Vadstena, Sweden) prior to the start of the experiment and then transferred to new cages and fasted for 24 h. Alternatively mice were treated with 0.1% WY-14,643 (Calbiochem-Novabiochem
International) in the diet for 1 week. All mice had access to water
ad libitum. Animals were sacrificed by CO2
asphyxiation followed by cervical dislocation and weighed immediately.
Tissues were then excised, weighed, and frozen in liquid nitrogen. For
subcellular fractionation experiments, livers from untreated wild-type
mice were homogenized directly after sacrifice.
Northern Blot Analysis--
Total RNA was isolated from mouse
tissue samples using QuickPrep® Total RNA Extraction Kit (Amersham
Biosciences Inc., Uppsala, Sweden), and Northern blot analysis
was carried out as described previously (7). Blots were probed
with the full-length cDNA for mouse PTE-2 or a probe for -actin
and were exposed to x-ray film at 70 °C.
Identification of Human PTE-2 Gene--
Using human
hACTEIII/hTE/hPTE1cDNA sequence (26-28) as search templates, a PAC
clone containing ~86 kb of human genomic sequence was found to
contain the gene encoding PTE-2. This human genomic sequence
(GenBankTM accession number AL008726) was downloaded from
NCBI (www.ncbi.nlm.nih.gov). The gene structure was compiled
using Lasergene Software Package and 5' splice donor sites and 3'
splice acceptor sites conformed to the general consensus sequences.
cDNA Cloning and Expression of PTE-2 in Escherichia
coli--
The sequence for hACTEIII/hTE/hPTE1 (26-28) was used to
search the mouse expressed sequence tag data base and several hits were
obtained. The full-length cDNA sequence was compiled from overlapping expressed sequence tag sequences. The mPTE-2
cDNA was amplified using the following primers:
5'-CATATGTCAGCGCCAGAGGGTCTG-3' and
5'-CATATGCTATAGCTTACTCTCTGACACCAG-3'. Both primers were constructed with the addition of an NdeI site,
indicated in bold. The full-length cDNA was amplified by reverse
transcriptase-PCR using a template of clofibrate-treated mouse
liver total RNA. PCR was performed in a PerkinElmer 2600 using the
Gene-Amp XL PCR kit (PE Biosystems). Thermal cycling was performed at
98 °C for 10 min followed by 35 cycles of 94 °C for 1 min,
64 °C for 1 min, and 72 °C for 4 min. The resultant PCR product
was cloned into the pCR-Script Amp (SK+) vector (Stratagene) and was
subsequently sequenced.
The full-length cDNA for PTE-2 was excised from pCR-Script
using NdeI restriction enzyme and cloned into the
NdeI site in pET16b vector (Novagen Inc.). Sequence analysis
was carried out to confirm the correct orientation. This plasmid was
then used to transform BL21 (DES3)pLysS cells (Novagen Inc.). For
expression of PTE-2, bacteria were cultured in 1 liter of Luria-Bertani
medium at 37 °C, with addition of ampicillin (50 µg/ml) and
chloramphenicol (34 µg/ml) until an A600 nm
of about 0.6 was reached. Induction of protein expression was performed
by addition of 1 mM
isopropyl-1-thio- -D-galactopyranoside, and growth was
continued overnight at room temperature. The bacteria were centrifuged
at 8,000 × gmax for 10 min at 4 °C and
the pellets were washed with 20 mM Tris, pH 8.0. The
pellets were then frozen at 20 °C. Pellets were thawed and
resuspended in 20 mM phosphate, 0.5 M sodium
chloride, and 10 mM imidazole, pH 7.4, and sonicated 5 × 5 s, at 5-s intervals. The sonicated bacteria were then
centrifuged at 36,000 × gmax for 1 h,
and the supernatant was used for purification of PTE-2 on a
HiTrapTM column (Amersham Biosciences, Inc.).
Following equilibration of the column, the supernatant was applied, and
the column was washed stepwise with 50, 100, 200, and 300 mM imidazole in 20 mM phosphate, 0.5 M sodium chloride, to remove contaminating proteins. The
PTE-2 protein was eluted using 500 mM imidazole, 20 mM phosphate, 0.5 M sodium chloride and was
subsequently used for acyl-CoA thioesterase activity measurements. The
purity of PTE-2 was examined by SDS-PAGE analysis and Coomassie
Brilliant Blue staining.
Localization of PTE-2 Using Green Fluorescent Fusion Protein and
Cell Transfection Experiments--
Oligonucleotides were designed
based on the sequence of the full-length cDNA for mouse PTE-2 for
cloning as a fusion protein with green fluorescent protein (GFP), to
examine targeting of the protein to peroxisomes. The full-length
cDNA was amplified by One Step RNA PCR kit (avian myeloblastosis
virus) (Takara Biomedicals) using the primers
5'-ATGTCAGCGCCAGAGGGTC-3' and 5'-CGAGCCAGGCATCTTTCAC-3' and was
cloned into the pcDNA3.1/NT-GFP vector (Invitrogen) in-frame with
the GFP at the N-terminal end. Sequence analysis was performed using
Big Dye Terminator (ABI Prism, PE Biosystems) and was sequenced by
Cybergene (Novum, Sweden).
Human skin fibroblasts from a control subject and a Zellweger patient
were grown in Eagle's minimum essential medium (Sigma), supplemented
with 10% fetal calf serum (Invitrogen) and 100 units of
penicillin/100 µg of streptomycin in an atmosphere of 5%
CO2. The Zellweger patient was a first-born, full-term
female with muscular hypotonia, convulsions, and dysmorphic
characteristics of Zellweger syndrome. The clinical diagnosis was
verified by the accumulation of very long-chain fatty acids with a
highly elevated C26/C22 ratio in cultured
fibroblasts. Both control and Zellweger cells were grown overnight in
60-mm dishes on glass coverslips and were transfected with 8 µg of
mPTE-2/GFP plasmid using the calcium phosphate method. Transfected
cells were grown for 48 h, washed twice with PBS, and fixed in
3.7% paraformaldehyde in PBS for 20 min on ice. Cells were
permeabilized in 0.5% Triton X-100 in PBS and rewashed in PBS.
Following blocking in 2% BSA in PBS, 0.1% Tween 20 for 1 h,
cells were incubated with rabbit green fluorescent protein antibody
(Molecular Probes, Leiden, The Netherlands) for 1 h and washed
four times with PBS, 2% BSA, and 0.1% Tween 20. Cells were then
incubated with CY3-conjugated affinity pure donkey anti-rabbit IgG
(Jackson ImmunoResearch) for 1 h. Cells were washed once with PBS,
0.1% Tween 20 (PBS-T) and nuclei were stained with Hoescht 33342 in
PBS-T for 10 min. Cells were again washed twice in PBS-T and were
mounted on glass slides using PPD (100 mg of
p-phenylenediamine, 90% glycerol, and 10% PBS) and
examined in Leica DM IRBE fluroescence microscope, using Hamamatsu
C4742-95 camera and C4742-95 Twain Interface software.
Determination of Acyl-CoA Thioesterase Activity--
Acyl-CoA
thioesterase activity was measured spectrophotometrically at 412 nm
with 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB). The medium contained
200 mM potassium chloride, 10 mM Hepes, and 0.05 mM DTNB, pH 7.4. An E412 = 13,600 m 1 cm 1 was used to calculate the
activity. Since PTE-2 thioesterase activity was inhibited at substrate
concentrations higher than 5-10 µM with acyl-CoAs longer
than C10, BSA was added to a molar ratio of BSA/acyl-CoA of
1:4.5. The effect of CoASH, DTNB, and p-chloromercuribenzoic
acid on enzyme activity was measured at 232 nm in phosphate buffered
saline. The enzyme kinetics were calculated using Sigma Plot enzyme
kinetics program.
Preparation and Characterization of Mouse Liver Subcellular
Fractions--
Livers from wild-type and PPAR -null mice were
homogenized as described previously (30), and bile acid-CoA
thioesterase activity was measured as described in Ref. 19. Livers from
untreated wild-type mice were fractionated as described (19). The
peroxisome-enriched fraction was further fractionated using a 15-45%
Optiprep gradient to obtain highly purified peroxisomes. Protein
concentrations were determined according to Bradford (31).
BAAT Assay--
The possible interference of PTE-2 on
peroxisomal BAAT activity was tested by addition of recombinant PTE-2
to incubations for BAAT activity. The reaction mixture contained the
following: 50 mM potassium phosphate buffer, pH 8.0, 25 µM [24-14C]chenodeoxycholoyl-CoA, 20 mM taurine, 60 µg BSA, 2.27 µg of mouse liver
peroxisomal protein, and 0.6 µg of purified recombinant PTE-2 in a
total volume of 150 µl. Control samples were as above, but with
inclusion of an equal volume HiTrapTM elution buffer (500 mM imidazole, 0.5 M sodium chloride, and 20 mM phosphate, pH 7.4) instead of PTE-2 protein. Following a 10-min preincubation at 37 °C, the reaction was started by addition of [24-14C]chenodeoxycholoyl-CoA and allowed to proceed
for 1 h. The reaction was terminated by addition of 45 µl of 1 M KOH. After 30-min hydrolysis at 70 °C, the mixture was
acidified using HCl and applied to a Sep-Pak C18-cartridge.
The radioactive compounds were eluted with 2-propanol and methanol and
analyzed by HPLC using a Beckman ODS 5 µ (4.6 mm × 25 cm)
column with 20% 30 mM trifluoroacetic acid (adjusted to pH
2.9 with triethylamine) in methanol as mobile phase. The eluents were
fractionated and assayed for 14C radioactivity by liquid
scintillation counting.
 |
RESULTS |
PTE-2 Cloning and Sequence Analysis--
The cDNA isolated for
PTE-2 encodes a protein of 320 amino acids, with a calculated molecular
mass of 35,886 Da. Alignment of the deduced amino acid sequence for
PTE-2 to the homologues in human (26-28), yeast (26), and E. coli (32) show the degree of sequence identity between the enzymes
(Fig. 1). The mouse and human sequences
show 85% sequence identity, the mouse and E. coli enzymes
show 40% identity at amino acid level, while the yeast and mouse
enzymes show 26% sequence identity. The amino acids elucidated to be
involved in the active site catalytic triad (33), Asp-233 (D), Ser-255
(S), and Gln-305 (Q) are conserved between species, except for
substitution of a threonine for serine in the E. coli
enzyme. However this substitution should not alter the catalytic site
capacity in view of the fact that both amino acids are polar.

View larger version (68K):
[in this window]
[in a new window]
|
Fig. 1.
Sequence alignment of acyl-CoA thioesterases
from mouse, human, yeast, and E. coli. Alignment
of mouse PTE-2, human PTE1 (26-28), yeast (Saccharomyces
cerevisiae) PTE1 (26) and E. coli Thioesterase
II (32) amino acid sequences was performed using the Clustal X method.
Amino acids conserved between the thioesterase sequences are
boxed in black. The active site aspartic acid (D)
233, serine/threonine (S/T) 255 and, glutamine
(Q) 305 residues of the catalytic triad are all indicated
with closed triangles.
|
|
Using bioinformatic techniques, we also identified the gene for human
PTE-2. The gene was identified on human chromosome 20q12-q13 and
comprised 6 exons, spaced by 5 introns, covering ~15.5-kb genomic DNA
(Fig. 2). The 5' splice donor sites and
3' splice acceptor sites conformed to recognized exon/intron consensus
sequences. Sequence analysis of the 5'-flanking region of the human
PTE-2 identified a putative direct repeat 1 element of GGGTCAaAGGTCA, at 438 upstream of the ATG start methionine.

View larger version (7K):
[in this window]
[in a new window]
|
Fig. 2.
Gene organization for human PTE-2. The
gene organization for human PTE-2 was determined as outlined under
"Experimental Procedures." Individual exon sizes are shown
(boxes), while intron sizes are shown underneath. A putative
direct repeat 1 element is indicated at 438 upstream of the ATG start
site.
|
|
PTE-2 Is Localized in Peroxisomes--
The mouse PTE-2 contains a
well characterized consensus peroxisomal Type 1 targeting signal of
-SKL (serine, lysine, leucine) at its C-terminal end, which has been
shown to target proteins to peroxisomes (34). Previously, human PTE-2
has been shown to be localized in peroxisomes (26, 35), and to test
whether mouse PTE-2 is peroxisomal, we cloned PTE-2 in-frame with GFP, which leaves the C-terminal -SKL sequence accessible. We transfected this vector into both control fibroblasts and fibroblasts from a
Zellweger patient, which are unable to import peroxisomal matrix proteins. Using immunofluorescence microscopy for GFP detection, mPTE-2
showed a punctate pattern of expression in control fibroblasts, indicative of a peroxisomal localization (Fig.
3A). This localization was
confirmed with a Tritc-labeled fluorescent secondary antibody to GFP
(Fig. 3B). However, in Zellweger fibroblasts, transfection of mPTE-2 resulted in a diffuse GFP expression (Fig. 3D).
The transfection of the Zellweger cells was confirmed using a
Tritc-labeled fluorescent secondary antibody to GFP, which identified
the transfected cells (Fig. 3E). Phase contrast microscopy
is also shown in both cases (Fig. 3, C and F) as
a control, indicating other untransfected cells. The strong staining
present in the nucleus is Hoescht staining.

View larger version (105K):
[in this window]
[in a new window]
|
Fig. 3.
PTE-2 is a peroxisomal matrix protein.
Human skin fibroblasts transfected with mPTE-2/GFP were processed for
immunofluorescence microscopy by fixing and permeabilizing with 0.5%
Triton X-100. The distribution of mPTE-2 was examined in control
fibroblasts using GFP fluorescence (A) and Tritc-labeled
anti-GFP antibody (B). The distribution of mPTE-2 in
Zellweger fibroblasts was also carried out using GFP fluorescence
(D) and Tritc-labeled anti-GFP antibody (E).
Phase contrast microscopy is shown in C and
F.
|
|
Recombinant Expression and Characterization of PTE-2--
The
cloning of the cDNA encoding PTE-2 into the NdeI site of
the pET16b vector results in expression of the PTE-2 as a His-tagged fusion protein, to allow for purification using affinity
chromatography. Following purification of PTE-2 on a
HiTrapTM column, the purified protein was detected as a
single band of ~36 kDa in mass on SDS-PAGE gel stained with Coomassie
Brilliant Blue (Fig. 4A). An
antibody toward the human PTE1 (a kind gift from Jacob Jones)
cross-reacted with the mouse PTE-2, confirming the correct protein
(data not shown). The expressed protein was further analyzed by
size-exclusion chromatography as described previously (36), using a
Superdex HR 200 10/30 column operated in a SMART micropurification
system (Amersham Biosciences Inc.). The recombinant PTE-2
protein eluted as an ~70-kDa protein, indicating a dimeric structure
of the expressed PTE-2, similar to the crystal structure of the
E. coli Thioesterase II enzyme (33).

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 4.
Kinetic characterization of recombinant mouse
PTE-2. Expression of recombinant PTE-2 in pET16b vector was
induced as described under "Experimental Procedures." A,
recombinant PTE-2 was purified on a HiTrapTM column, and
the purified protein was subjected to SDS-PAGE analysis and staining
with Coomassie Brilliant Blue. Sizes of molecular weight markers are
indicated. B, enzyme activity measurements were determined
using purified PTE-2 as an enzyme source. Acyl-CoA thioesterase
activity was measured with various concentrations of palmitoyl-CoA ± BSA at an albumin to substrate molar ratio of 1:4.5. C,
acyl-CoA thioesterase activity on various CoA esters using purified
PTE-2 as an enzyme source. Acyl-CoA thioesterase activity was measured
with a 10 µM concentration of the indicated CoA ester, in
the presence of BSA at a substrate to albumin molar ratio of 4.5:1 for
CoA esters longer than C10. Cn, number of
carbons; PGF2 , prostaglandin
F2 -CoA, 2-CH3-C18,
2-methylstearoyl-CoA; Mal, malonyl-CoA; AcAc,
acetoacetyl-CoA. D, inhibition of PTE-2 activity by CoASH.
Acyl-CoA thioesterase activity was measured at 232 nm as described
under "Experimental Procedures." The activity was measured using
octanoyl-CoA as substrate, to avoid the required addition of BSA, which
will strongly interfere at 232 nm when measuring activity with longer
acyl-CoAs. CoASH was added to the enzyme assay at concentrations
indicated.
|
|
Following initial enzyme activity characterization of the recombinant
protein, it was evident that PTE-2 activity was inhibited at substrate
concentrations >5-10 µM for long-chain acyl-CoAs. However, addition of BSA to an albumin/acyl-CoA ratio of 1:4.5 to the
reaction prevented inhibition (Fig. 4B). Recombinant PTE-2 was analyzed for acyl-CoA thioesterase activity, which was determined at several concentrations with substrates of different chain lengths. Surprisingly, PTE-2 showed similar activity toward all acyl-CoAs tested
ranging from C2 up to C20 straight-chain
acyl-CoAs, together with activity toward long-chain unsaturated
acyl-CoAs (Fig. 4C). Interestingly, PTE-2 also efficiently
catalyzed the hydrolysis of CoA esters of bile acids, namely
choloyl-CoA and chenodeoxycholoyl-CoA, at an ~3 times higher rate
than with straight-chain acyl-CoAs, with THCA-CoA also being hydrolyzed
at a high rate. The CoA esters of other substrates found in peroxisomes
were also analyzed. PTE-2 hydrolyzed 3-hydroxy-3-methyl-glutaryl-CoA
(HMG-CoA), branched-chain CoA esters (4,8-dimethylnonanoyl-CoA and
2-methylstearoyl-CoA), the CoA ester of prostaglandin
F2 , and acetoacetyl-CoA.
If PTE-2 is a major thioesterase in peroxisomes controlling
CoASH levels, it is feasible that it may be directly regulated by
CoASH. Indeed PTE-2 activity was strongly inhibited by CoASH with an
IC50 of ~10-15 µM (Fig. 4D).
PTE-2 activity was also inhibited by DTNB (IC50 150 µM) and p-chloromercuribenzoic acid
(IC50 1 µM), two cysteine-reactive agents
(data not shown); however, to date a cysteine involved in the active
site catalysis has not been identified.
Calculation of the Vmax and
Km values showed that the Km for
medium- to long-chain acyl-CoAs was in the order of 1.4-6.7
µM, with short-chain acyl-CoAs ranging from 8 to 30 µM (Table I). The
Km for bile acid-CoA esters was in the range of
9-15 µM. PTE-2 also hydrolyzed -oxidation intermediates such as 2-trans-decenoyl-CoA and 3-hydroxypalmitoyl-CoA, although at ~20% of the rates of decanoyl-CoA and palmitoyl-CoA. All
Km values are rather low, strongly suggesting that all these CoA esters are substrates for PTE-2 in vivo.
View this table:
[in this window]
[in a new window]
|
Table I
Calculated Km and Vmax values for recombinant PTE-2
Thioesterase activity with different CoA esters were measured at
different substrate concentrations. Activities were measured as
described under "Experimental Procedures" using 0.3-1.2 µg of
purified recombinant PTE-2. Km and
Vmax values were calculated using Sigma Plot Enzyme
Kinetic program. ND, not determined.
|
|
Recombinant PTE-2 and Isolated Mouse Liver Peroxisomes Show
Strikingly Similar Acyl-CoA Thioesterase Substrate
Specificities--
The acyl-CoA thioesterase chain length specificity
was measured in isolated mouse peroxisomes (Fig.
5A). Activity was seen with
straight-chain acyl-CoAs from chain length of C2 up to
C20, together with very high activity toward bile acid-CoA
esters, THCA-CoA, and branched-chain CoA esters. There was a striking similarity between the acyl-CoA chain length pattern for the
recombinant PTE-2 and the chain length specificity in isolated
peroxisomes (Fig. 5B). Superimposing the curves for the
substrate specificities of isolated peroxisomes and that of PTE-2
showed that PTE-2 apparently catalyzes most of the activities seen in
peroxisomes, with the only observable difference being the putative
presence of an additional acyl-CoA thioesterase in peroxisomes, mainly
catalyzing the hydrolysis of C12-C14-CoA.
Comparison of the specific activities of recombinant PTE-2 and isolated
peroxisomes indicates that PTE-2 constitutes about 1% of total
peroxisomal protein.

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 5.
Acyl-CoA thioesterase substrate specificity
in purified peroxisomes and for recombinant PTE-2. A,
acyl-CoA thioesterase activity measurements were determined in 2.27 µg of purified peroxisomes from wild-type mice treated with 0.1%
WY-14,643 for 1 week, using a 25 µM concentration of
various acyl-CoA esters. B, enzyme activity measurements
were determined using purified PTE-2 as an enzyme source, using
0.3-1.2 µg of recombinant PTE-2 and 25 µM acyl-CoA as
substrate.
|
|
PTE-2 Competes with Bile Acid-CoA:Amino Acid N-Acyltransferase for
Bile Acid-CoA--
We examined the ability of recombinant PTE-2 to
compete with BAAT for the bile acid-CoA substrate
chenodeoxycholoyl-CoA. BAAT activity was measured in highly purified
peroxisomes isolated from control mouse liver. Addition of recombinant
PTE-2 caused an ~80% inhibition of BAAT activity (Table
II). These data show that PTE-2 can
compete with BAAT for the bile acid-CoA substrate in vitro.
We have also tested the ability of recombinant mouse cytosolic acyl-CoA
thioesterase I (mCTE-I) (37) to hydrolyze CA-CoA or CDCA-CoA. However,
this enzyme showed no detectable activity with CA-CoA or CDCA-CoA,
further emphasizing that the bile acid-CoA thioesterase activity of
PTE-2 is specific (data not shown).
View this table:
[in this window]
[in a new window]
|
Table II
Specific activity of bile acid-CoA:amino acid N-acyltransferase (BAAT)
in purified peroxisomes from untreated wild-type mice
Addition of recombinant PTE-2 to the incubation mixture and detection
of tauro-chenodeoxycholic acid formation was as described in
"Experimental Procedures." All samples were measured in duplicate.
|
|
Choloyl-CoA Thioesterase Activity Is Induced in Mouse
Liver in a PPAR -dependent Manner--
Since PTE-2 very
efficiently hydrolyzes CoA esters of bile acids, and PPAR has been
shown to be involved in bile acid biosynthesis (38), we investigated
the possible regulation of bile acid-CoA thioesterase activity by
feeding mice WY-14,643, a potent PPAR activator. In liver
homogenates of wild-type mice, choloyl-CoA thioesterase activity was
increased 3.5-fold following treatment with WY-14,643 (Fig.
6). However in PPAR -null mouse liver
homogenates, this increase in choloyl-CoA thioesterase activity was not
evident, showing that the WY-14,643-mediated induction of bile acid-CoA thioesterase activity in mouse liver was
PPAR -dependent.

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 6.
Bile acid-CoA thioesterase activity is
increased in mouse liver homogenates by WY-14,643 treatment.
Specific choloyl-CoA thioesterase activity was measured as described
under "Experimental Procedures" in homogenates from untreated
PPAR wild-type (+/+) and null ( / ) mice and
mice treated with 0.1% WY-14,643 (WY) for 1 week.
|
|
PTE-2 mRNA Expression Is PPAR -regulated--
In view of the
fact that PTE-2 can hydrolyze bile acid-CoA esters, together with the
fact that choloyl-CoA thioesterase activity was shown to be induced in
a PPAR -dependent manner in mouse liver, we used the
PPAR -null mouse model to examine regulation of the PTE-2 at mRNA
level. The basal expression of PTE-2 in PPAR -null mice was
approximately half that detected in wild-type animals. Treatment of
mice with a WY-14,643-containing diet for 1 week resulted in a very
strong (>10-fold) induction of PTE-2 mRNA (Fig. 7A, upper panel).
However, this up-regulation was not evident in the PPAR -null mice
also treated with WY-14,643, showing that the effect mediated on PTE-2
by peroxisome proliferators is dependent on the PPAR .

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 7.
Northern blot analysis of PTE-2 mRNA
expression in mouse liver. A, upper panel,
groups of six PPAR -null mice ( / ) or age-matched
wild-type mice (+/+) were fed 0.1% WY-14,643 for 1 week,
while control animals had access to normal chow diet ad
libitum. Mice were sacrificed, and total RNA was isolated from
liver. Northern blot analysis was carried out on 20 µg of total RNA
using -32P-labeled cDNA probe for PTE-2 as described
under "Experimental Procedures." A representative blot with two
samples per group is shown together with the ethidium bromide staining
of the blot with positions of the 28 and 18 S bands indicated. Lower panel,
Northern blot analysis of mouse liver total RNA from control mice or
mice fasted for 24 h. B, PTE-2 mRNA expression
shows diurnal variation. C57 BL/6 mice were maintained on a normal chow
diet ad libitum and were sacrificed at the time points
indicated. The light period was between 06.00 and 18.00 and the dark
period between 18.00 and 06.00. Northern blot analysis was carried out
on 20 µg of total RNA using -32P-labeled probes for
PTE-2 and -actin. Filters were exposed to x-ray film, and signals
were quantified using Image Master Software 3.0. The mean of
PTE-2/actin mRNA ± range for two animals is shown.
C, tissue expression of PTE-2 mRNA. Total RNA was
isolated from various tissues of Sv129 male mice. Northern blot
analysis was carried out on 20 µg of total RNA using
-32P-labeled cDNA probe for PTE-2 as described under
"Experimental Procedures." Ethidium bromide (EtBr)
staining of the gel shows even loading of samples.
|
|
The role of the PPAR in the fasting-mediated induction of several
genes has also been shown (7-10, 38). We examined the effect of
fasting on PTE-2 mRNA levels in the PPAR -null mouse model, which
resulted in a significant increase in PTE-2 mRNA in liver (Fig.
7A, lower panel). However, this induction was not seen in the PPAR -null mice that were similarly treated.
PTE-2 Shows a Diurnal Regulation of Expression--
As PTE-2 is
regulated by fasting and is therefore under nutritional regulation, we
examined whether this enzyme could also be under a diurnal regulation.
Mice were fed a normal chow diet and were sacrificed every 4th h
commencing at 09.00 h. Quantitation of the mRNA signal showed that
during the light period (between 06.00 and 18.00 h), when animals are
less active, the mRNA levels were increased, thus indicating an
induction by fasting (Fig. 7B). During the dark period, when
feeding mainly takes place (between 18.00 and 06.00 h) the mRNA
levels declined rapidly, indicating a rapid nutritional regulation in
response to refeeding.
PTE-2 mRNA Is Ubiquitously Expressed--
The tissue
expression of PTE-2 was examined using Northern blot analysis on
several different tissues from mouse (Fig. 7C). PTE-2 was
ubiquitously expressed as a 1.2-kb transcript in all tissues examined,
which is similar to results obtained for expression in human tissues
(27). Tissue expression was highest in kidney, liver, and testis, with
weaker expression evident in heart and muscle. In testis a second
transcript was evident at ~2 kb, which may be due to splicing events.
PTE-2 is therefore widely expressed in tissues, similar to that of the
peroxisomal -oxidation enzymes acyl-CoA oxidase,
L-bifunctional enzyme and 3-ketoacyl-CoA thiolase (39).
 |
DISCUSSION |
In this study we have cloned and characterized the mouse
peroxisomal acyl-CoA thioesterase 2, called PTE-2, which is localized in peroxisomes. This enzyme is the mouse homologue of human PTE1 (26),
which was first identified by the yeast two-hybrid system as hACTEIII
and hTE, a HIV-1 Nef-binding protein (27, 28). There is a lot of
confusion regarding the nomenclature of acyl-CoA thioesterases, and
based on a recent attempt to accomplish a more uniform terminology
(16), we propose the name PTE-2 for this acyl-CoA thioesterase, as the
nomenclature PTE-I has already been assigned to two enzymes that are
members of a novel multigene family, with other members in mitochondria
and cytosol (25) (Table III).
However, the rule applied to the nomenclature of yeast enzymes states
that they remain known by the name applied when they were first
identified, therefore this enzyme will remain known as PTE1. A human
PTE2 cloned as a putative peroxisomal enzyme (40) (Table III) shows
100% identity to human MTE-I (mitochondrial acyl-CoA thioesterase)
without its N-terminal sequence. This MTE-I belongs to a novel family
of acyl-CoA thioesterases in human, with localizations also in cytosol
and peroxisomes.2
The HIV-1 Nef, which interacts with the thioesterase PTE-2, is a
cytosolic 27-kDa myristoylated protein that is required for high viral
load and full pathological effect of HIV (41). It is thought that Nef
activity triggers endocytosis of CD4 and major histocompatibility
complex class-I molecules. Although the interaction of Nef with the
acyl-CoA thioesterase is not fully understood, it has been shown that
Nef contains sites critical for binding of the human thioesterase,
which results in down-regulation of CD4 (35). The binding of Nef to the
thioesterase also targets Nef to peroxisomes in vivo and
increases thioesterase activity in vitro (27). It was also
shown that abolishment of the interaction of the thioesterase with Nef
resulted in impairment of Nef biological functions (42). It then became
evident that although this thioesterase may have a putative function in
the pathogenesis of HIV, the enzyme may also be involved in fatty acid
metabolism. In 1999, Jones et al. (26) again characterized
this enzyme in human, which they named PTE1, together with a yeast
homologue, showing these proteins are targeted to the peroxisomal
lumen. The yeast PTE1 identified showed regulation at mRNA level by
growth on oleate. In yeast, -oxidation of fatty acids is confined
only to peroxisomes, and growth of yeast on oleate as sole carbon
source results in increased expression of peroxisomal enzymes and
proliferation of peroxisomes. Disruption of PTE1 in yeast resulted in a
loss of approximately 80% of total cellular thioesterase activity, demonstrating that PTE1 is the major long-chain acyl-CoA thioesterase in yeast grown on oleate. Furthermore, this deletion impaired growth on
oleate, suggesting that efficient -oxidation in yeast requires the
expression of this thioesterase, possibly to closely regulate the
intraperoxisomal CoASH levels. Our data now suggest that PTE-2 is in
fact a major acyl-CoA thioesterase, which can hydrolyze a wide variety
of CoA esters in peroxisomes also in the mouse. The difference in
acyl-CoA chain length specificity of PTE-2 in our study compared with
previous studies is due to the inclusion of albumin to the thioesterase
assay when measuring activity with acyl-CoAs longer than decanoyl-CoA.
With addition of albumin, it became evident that PTE-2 hydrolyzes all
acyl-CoAs of two carbons up to twenty carbons with very similar
Vmax. The inhibition of PTE-2 activity by CoASH
indicates that this enzyme can "sense" intraperoxisomal CoASH
levels, and thus when there is a requirement for CoASH, PTE-2 is
active, whereas during times of high free CoASH, PTE-2 can be
inhibited. Peroxisomes contain a distinct pool of CoASH (43, 44), which
has been reported to change during fasting and treatment with
peroxisome proliferators (45). The extent of CoASH sequestration may
therefore depend on the size of the CoASH pool, the amount and type of
lipids being trapped in the -oxidation systems in the peroxisome, as
well as activities of acyl-CoA thioesterases and possibly a recently cloned peroxisomal nudix hydrolase, which apparently can hydrolyze CoASH to yield 3',5'-ADP and the corresponding 4'-phosphopantetheine derivative (46).
PTE-2 Can Have a Multitude of Functions in Regulating Peroxisomal
Lipid Metabolism--
In the present study we have cloned and
characterized the mouse PTE-2 with respect to regulation of expression
and kinetic activity. Recombinant PTE-2 hydrolyzed all tested CoA
esters, showing an almost complete lack of substrate specificity with respect to the carboxylic acid moiety. The enzyme catalyzes the hydrolysis of straight-chain, saturated and unsaturated acyl-CoAs of
2-20 carbons in chain length with roughly similar
Vmax. The enzyme also hydrolyzed other CoA
esters such as acetoacetyl-CoA, malonyl-CoA, HMG-CoA, clofibroyl-CoA,
THCA-CoA and CoA esters of bile acids, and -oxidation intermediates.
This apparent lack of substrate specificity suggests that the binding
site of the enzyme is rather nonspecific with respect to the acyl
moiety and that the enzyme may recognize the CoASH moiety for binding.
This is in line with the observed inhibitory effect of free CoASH, the
kinetics of which suggested a competitive mode of action, although the
data were not fully conclusive. Notably, all the CoA esters tested as
substrates for PTE-2 can be expected to be present in peroxisomes as
substrates, intermediates, or end products in lipid metabolism. In
combination with the strong regulation of expression via PPAR , the
PTE-2 thioesterase may have a multitude of functions in peroxisomes as
outlined in Fig. 8. Fatty acids and other
substrates for -oxidation in peroxisomes must first be esterified to
their CoA ester. CoASH that is appended to poorly oxidizable substrates
may cause a trapping of CoASH and thereby prevent the -oxidation
cycle to continue. Thus, PTE-2 may temporarily hydrolyze substrates for
the -oxidation to release CoASH. We also tested CoA esters of
-oxidation intermediates, 2-trans-decenoyl-CoA and
3-hydroxypalmitoyl-CoA. Both these CoA esters were poorer substrates
compared with the corresponding straight-chain acyl-CoA: 2-trans-decenoyl-CoA was hydrolyzed at a rate of about 22% of that
observed with decanoyl-CoA with the Km being
increased 6-fold and Vmax being decreased, and
3-hydroxypalmitoyl-CoA, which was hydrolyzed at a rate of about 18% of
the rate of hydrolysis of palmitoyl-CoA, with the Km
being similar but Vmax being much lower. The
lower activities of PTE-2 with -oxidation intermediates indicates
that the thioesterase preferentially removes the CoA esters of
substrates and end products, while -oxidation intermediates are
allowed to be further oxidized.

View larger version (41K):
[in this window]
[in a new window]
|
Fig. 8.
Model for putative functions of PTE-2 in
peroxisomes. PTE-2 may function as an auxillary enzyme in
-oxidation of a number of substrates in peroxisomes. The
abbreviations used are: VLCFA, very long-chain fatty acids:
CAT, carnitine acetyltransferase; COT, carnitine
octanoyltransferase; PG, prostaglandins: LT,
leukotrienes; Tb, thromboxanes; FFA, free fatty
acid; Cn, carnitine.
|
|
However, a number of carboxylic acids, such as prostaglandins,
leukotrienes, and thromboxanes are chain-shortened in peroxisomes and
excreted in the urine as the free acids, thus requiring an acyl-CoA
thioesterase for these processes. The finding in the present study that
PTE-2 readily hydrolyzes the CoA ester of prostaglandin F2 is the first demonstration of an acyl-CoA
thioesterase that can have this function.
In the -oxidation of pristanic acid, the intermediate
4,8-dimethylnonanoyl-CoA (DMN) is formed and is transported from the peroxisome to the mitochondria as a carnitine ester, for further oxidation. The high activity of recombinant PTE-2 toward DMN-CoA indicates that PTE-2 may also be able to hydrolyze DMN-CoA to DMN and
release CoASH for other -oxidation reactions in peroxisomes if
required. The DMN could then be re-esterified to CoASH by the very
long-chain acyl-CoA synthetase in peroxisomes (47).
PTE-2 Is a PPAR Target Gene That May Regulate Bile Acid
Formation--
Bile acids are formed in liver peroxisomes by
-oxidative cleavage of the side chain of DHCA-CoA or THCA-CoA to
chenodeoxycholoyl-CoA and choloyl-CoA, respectively, with the
concomitant production of propionyl-CoA. In the last step, bile
acid-CoAs are conjugated to taurine or glycine, a reaction catalyzed by
the BAAT enzyme that acts as an acyltransferase. In fact the best
substrates for PTE-2 were found to be THCA-CoA, CA-CoA, and CDCA-CoA.
We have now established that PTE-2 is the bile acid-CoA thioesterase
identified previously (19, 20), suggesting that a major function of the PTE-2 in liver may be in regulation of bile acid formation and excretion. This conclusion is further supported by the competition experiment carried out, which showed that addition of a small amount of
recombinant PTE-2 to peroxisomes severely suppresses the activity of
BAAT, presumably due to consumption of the substrate CDCA-CoA. PPAR
has been established as a key regulator of lipid metabolism, but was
also shown to be involved in regulation of bile acid metabolism (38),
thus connecting the pathways of bile acid and fatty acid metabolism.
Up-regulation of PTE-2 by WY-14,643, together with the
PTE-2-mediated suppression of bile acid conjugation with taurine in vitro, could imply that PPAR is also
involved in regulating bile acid amidation. Indeed, preliminary data
show a reduction in conjugated bile acids in mouse liver following treatment with WY-14,643.3
This functional aspect may be very important in view of the recent interest in the farnesoid-X-receptor (FXR), a nuclear receptor that
acts as a biological sensor for the regulation of bile acid biosynthesis, and that is activated by free and conjugated
chenodeoxycholic acid (48, 49) and cholic acid (50). The FXR/RXR
regulates expression of genes involved in bile acid metabolism, such as the human ileal bile acid-binding protein (51) and cholesterol 7 -hydroxylase (52, 53). Increased PTE-2 activity would therefore result in an increase in free bile acids, which may subsequently be
transported to the nucleus to activate the FXR/RXR heterodimer complex.
In this way, PTE-2 may mediate cross-talk between the PPAR and the
FXR signaling pathways.
With the identification of the gene for the human PTE-2, a putative
peroxisome proliferator-response element was identified at 438 bp
upstream of the ATG start site. This site conforms well to the
consensus direct repeat 1 (AGGTCAnAGGTCA), which has been shown to bind
both PPAR/RXR heterodimers and hepatocyte nuclear factor 4 . It will
be of interest to identify if this site is functional in the human
promoter in binding these transcription factors, thus leading to
possible activation of human PTE-2 by either peroxisome proliferators
or fatty acids (the ligands for PPARs (3, 4)), or acyl-CoAs and CoA
esters of peroxisome proliferators (the agonists/antagonists for
hepatocyte nuclear factor 4 (54, 55)).
Can PTE-2 Be Considered as an Auxilliary -Oxidation
Enzyme?--
In addition to bile acid intermediates, PTE-2 efficiently
hydrolyzes methyl-branched fatty acids (e.g.
4,8-dimethylnonanoyl-CoA and 2-methylstearoyl-CoA), which are
substrates of the "branched-chain" -oxidation pathway in
peroxisomes. Branched-chain CoA esters appear to be excellent
substrates for PTE-2, but are generally slowly metabolized via
-oxidation in peroxisomes. At first sight, there appears to be a
paradoxical situation that an acyl-CoA thioesterase should facilitate
degradation of lipids. However, as outlined before, it is probably very
important that appropriate CoASH levels are maintained in peroxisomes.
Such a function is supported by the findings in yeast that deletetion
of the gene encoding the yeast homologue PTE1 impairs growth of the
PTE1 knock-out strain on oleate. Therefore, a possible function of
PTE-2 may be to act as an auxilliary enzyme in -oxidation of
branched-chain fatty acids/bile acid formation. This -oxidation
pathway is not PPAR -regulated, and therefore the PPAR -mediated
up-regulation of PTE-2 may function in salvaging CoASH for
-oxidation of fatty acids or alternatively function in (temporarily)
decreasing -oxidation of branched-chain lipids. This could serve to
mediate a metabolic cross-talk between PPAR and degradation of this
class of lipids in the liver. It should be stressed that it is very
likely that PTE-2 can play different functions in different organs
which could be related to organ-specific metabolic function of
peroxisomes in different tissues.
Is PTE-2 Involved in Regulation of Cholesterol
Synthesis in Peroxisomes?--
As outlined above, the PPAR
regulation of PTE-2 may confer a metabolic crosstalk between fatty acid
degradation and cholesterol metabolism. A similar metabolic cross-talk
may occur by PPAR regulation of PTE-2 activity, which may interefere
with peroxisomal cholesterol biosynthesis. The initial enzymes involved
in cholesterol synthesis have been demonstrated to be present in
peroxisomes. These enzymes include acetoacetyl-CoA thiolase (56),
HMG-CoA synthase (57), and HMG-CoA reductase (58, 59). PTE-2 hydrolyzes acetyl-CoA (substrate for acetoacetyl-CoA thiolase), acetoacetyl-CoA (substrate for HMG-CoA synthase), and HMG-CoA (substrate for the HMG-CoA reductase). In addition, while the peroxisomal HMG-CoA reductase is up-regulated 2 h into the light cycle (60), PTE-2 is
most highly expressed at the end of the light cycle/beginning of the
dark cycle, indicating a functionally coordinated regulation of
expression, i.e. high expression of PTE-2 when HMG-CoA
reductase is expressed at low levels.
Role of PTE-2 in Regulation of Short-chain Acyl-CoAs Generated from
Peroxisomal -Oxidation--
-Oxidation of straight-chain and
branched-chain fatty acids produces chain-shortened acyl-CoAs, which
may be transferred to mitochondria (as carnitine esters) for further
metabolism or be excreted in urine. However, for each cycle in the
-oxidation, acetyl-CoA and propionyl-CoA are also produced.
Accumulation of propionyl-CoA can be associated with impaired
metabolism (61). Propionyl-CoA is formed from the -oxidation of
pristanoyl-CoA and other branched-chain acyl-CoAs and bile acid
intermediates in peroxisomes. This propionyl-CoA may be transferred to
carnitine by peroxisomal carnitine acetyltransferase for further
metabolism in mitochondria or hydrolyzed to propionic acid.
Propionyl-CoA thioesterase activity has previously been identified in
peroxisomes (23, 24). Our present data show that PTE-2 can efficiently hydrolyze propionyl-CoA with a Km of <10
µM and a Vmax of about 3.45 µmol/min/mg of protein. Therefore PTE-2 could prevent accumulation of
propionyl-CoA and thus release free CoASH for other reactions. In a
similar manner, acetyl-CoA units are released during -oxidation of
both very long- and long-chain acyl-CoAs and dicarboxylic acids and are
then transferred to carnitine by carnitine acetyltransferase for
further metabolism in mitochondria or hydrolyzed to acetate and
excreted to cytosol. Free acetate can account for total acetyl-CoA
produced in peroxisomes from dicarboxylic and monocarboxylic acids, and
acetate production is increased by peroxisome proliferator treatment
(62). The production of free acetate from acetyl-CoA requires the
hydrolysis by an acyl-CoA thioesterase present in peroxisomes (23, 24). Again, recombinant PTE-2 showed high activity toward acetyl-CoA, which
constitutes a mechanism to prevent trapping of CoASH in the acetyl-CoA unit.
In summary, we have shown that PTE-2 acts as a general acyl-CoA
thioesterase that is responsible for most of the thioesterase activity
detected in isolated peroxisomes. Furthermore, PTE-2 is highly
regulated by WY-14,643 and fasting, which identifies PTE-2 as a novel
PPAR target gene. Based on the regulation of expression and
regulation of enzymatic activity by CoASH levels, it is likely that
PTE-2 has important functions in regulating peroxisomal lipid
metabolism. We therefore propose that PTE-2 is a major thioesterase
found in peroxisomes that may regulate intracellular peroxisomal CoASH
levels, controlling -oxidation of a broad range of acyl-CoA
metabolites and the levels of free and conjugated bile acids in liver.
PTE-2 could also be a candidate gene for some of the hitherto
unidentified disorders of peroxisomal fatty acid metabolism. Targeted
disruption of the gene for PTE-2 should provide an interesting model to
examine the role of this enzyme in many of the diverse metabolic
pathways in peroxisomes.
 |
ACKNOWLEDGEMENTS |
We thank Frank Gonzalez and Jeffrey Peters
for PPAR -null mice, Jacob Jones for PTE1 antibody, Jan Pedersen for
THCA-CoA and 2-methylstearoyl-CoA, Ronald Wanders for
4,8-dimethylnonanoyl-CoA, Kilervo Hiltunen for 2-trans-decenoyl-CoA,
Nikolaos Venizelos for 3-hydroxypalmitoyl-CoA, Manfred Held for
synthesis of the prostaglandin F2 -CoA ester, and Kjell
Hultenby for GFP antibody. We also gratefully acknowledge the advice
and assistance of Cecilia Rustum and Einar Hallberg regarding GFP
experiments and for the GFP secondary antibody.
 |
FOOTNOTES |
*
This work was supported by the Swedish Society for Medical
Research, the Swedish Medical Research Council, the Swedish Natural Science Research Council, Hjärt-Lungfonden, and Amersham
Biosciences, Inc.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EBI Data Bank with accession number(s) AF441166.
To whom correspondence should be addressed: Dept. of Medical
Laboratory Sciences and Technology, Division of Clinical Chemistry C1-74, Karolinska Institutet, Huddinge University Hospital, SE-141 86 Stockholm, Sweden. Tel.: 46-8-58581293; Fax: 46-8-58581260; E-mail:
mary.hunt@chemlab.hs.sll.se.
§
Present address: Inst. for Nutrition Research, University of Oslo,
NO-0316 Oslo, Norway.
Published, JBC Papers in Press, October 22, 2001, DOI 10.1074/jbc.M106458200
2
M. C. Hunt, A. Rautanen, T. L. T. Svensson,
and S. E. H. Alexson, manuscript in preparation.
3
K. Solaas, M. C. Hunt, V. Pham, G. Alvelius, K. Hultenby, B. F. Kase, and S. E. H. Alexson, manuscript in preparation.
 |
ABBREVIATIONS |
The abbreviations used are:
PPAR , peroxisome proliferator-activated receptor ;
CoA, coenzyme A;
PTE-2, peroxisomal acyl-CoA thioesterase-2;
CoASH, coenzyme A, reduced;
THCA-CoA, trihydroxycoprostanoyl-CoA;
DHCA, dihydroxycoprostanoyl-CoA;
CA-CoA, choloyl-CoA;
CDCA-CoA, chenodeoxycholoyl-CoA;
DMN-CoA, 4,8-di-methylnonanoyl-CoA;
HMG-CoA, 3-hydroxy-3-methyl-glutaryl-CoA;
BAAT, bile acid-CoA:amino acid
N-acyltransferase;
FXR, farnesoid-X-receptor;
RXR, retinoid-X-receptor;
BSA, bovine serum albumin;
PBS, phosphate-buffered
saline;
HPLC, high-pressure liquid chromatography;
GFP, green
fluorescent protein;
DTNB, 5,5'-dithiobis(2-nitrobenzoic acid);
Tritc, tetramethylrhodamine-5-isothiocyanate;
HIV, human immunodeficiency
virus.
 |
REFERENCES |
| 1.
|
Van Veldhoven, P. P.,
and Mannaerts, G. P.
(1999)
Adv. Exp. Med. Biol.
466,
261-272
|
| 2.
|
Reddy, J. K.,
and Hashimoto, T.
(2001)
Annu. Rev. Nutr.
21,
193-230
|
| 3.
|
Forman, B. M.,
Chen, J.,
and Evans, R. M.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
4312-4317
|
| 4.
|
Kliewer, S. A.,
Sundseth, S. S.,
Jones, S. A.,
Brown, P. J.,
Wisely, G. B.,
Koble, C. S.,
Devchand, P.,
Wahli, W.,
Willson, T. M.,
Lenhard, J. M.,
and Lehmann, J. M.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
4318-4323
|
| 5.
|
Lee, S. S.,
Pineau, T.,
Drago, J.,
Lee, E. J.,
Owens, J. W.,
Kroetz, D. L.,
Fernandez-Salguero, P. M.,
Westphal, H.,
and Gonzalez, F. J.
(1995)
Mol. Cell. Biol.
15,
3012-3022
|
| 6.
|
Aoyama, T.,
Peters, J. M.,
Iritani, N.,
Nakajima, T.,
Furihata, K.,
Hashimoto, T.,
and Gonzalez, F. J.
(1998)
J. Biol. Chem.
273,
5678-5684
|
| 7.
|
Hunt, M. C.,
Lindquist, P. J. G.,
Peters, J. M.,
Gonzalez, F. J.,
Diczfalusy, U.,
and Alexson, S. E. H.
(2000)
J. Lipid Res.
41,
814-823
|
| 8.
|
Kroetz, D. L.,
Yook, P.,
Costet, P.,
Bianchi, P.,
and Pineau, Y.
(1998)
J. Biol. Chem.
273,
31581-31589
|
| 9.
|
Kersten, S.,
Seydoux, J.,
Peters, J. M.,
Gonzalez, F. J.,
Desvergne, B.,
and Wahli, W.
(1999)
J. Clin. Invest.
103,
1489-1498
|
| 10.
|
Leone, T. C.,
Weinheimer, C. J.,
and Kelly, D. P.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
7473-7478
|
| 11.
|
Lewin, T. M.,
Kim, J. H.,
Granger, D. A.,
Vance, J. E.,
and Coleman, R. A.
(2001)
J. Biol. Chem.
276,
24674-24679
|
| 12.
|
Gargiulo, C. E.,
Stuhlsatz-Krouper, S. M.,
and Schaffer, J. E.
(1999)
J. Lipid Res.
40,
881-892
|
| 13.
|
Yamada, J.,
Itoh, S.,
Horie, S.,
Watanabe, T.,
and Suga, T.
(1986)
Biochem. Pharmacol.
35,
4363-4368
|
| 14.
|
Yamada, J.,
Ogawa, S.,
Horie, S.,
Watanabe, T.,
and Suga, T.
(1987)
Biochim. Biophys. Acta
921,
292-301
|
| 15.
|
Diczfalusy, U.
(1994)
Prog. Lipid Res.
33,
403-428
|
| 16.
| Hunt, M. C., and Alexson, S. E. H. (2001) Prog.
Lipid Res., in press
|
| 17.
|
Pedersen, J. I.,
and Gustafsson, J.
(1980)
FEBS Lett.
121,
345-348
|
| 18.
|
Kase, F.,
Björkhem, I.,
and Pedersen, J. I.
(1983)
J. Lipid Res.
24,
1560-1567
|
| 19.
|
Solaas, K.,
Ulvestad, A.,
Söreide, O.,
and Kase, B. F.
(2000)
J. Lipid Res.
41,
1154-1162
|
| 20.
|
Solaas, K.,
Sletta, R. J.,
Søreide, O.,
and Kase, B. F.
(2000)
Scand. J. Clin. Invest.
60,
91-102
|
| 21.
|
Osmundsen, H.,
Neat, C. E.,
and Borrebaek, B.
(1980)
Int. J. Biochem.
12,
625-630
|
| 22.
|
Berge, R. K.,
Flatmark, T.,
and Osmundsen, H.
(1984)
Eur. J. Biochem.
141,
637-644
|
| 23.
|
Alexson, S. E. H.,
Osmundsen, H.,
and Berge, R. K.
(1989)
Biochem. J.
262,
41-46
|
| 24.
|
Wilcke, M.,
and Alexson, S. E. H.
(1994)
Eur. J. Biochem.
222,
803-811
|
| 25.
|
Hunt, M. C.,
Nousiainen, S. E. B.,
Huttunen, M. K.,
Orii, K.,
Svensson, L. T.,
and Alexson, S. E. H.
(1999)
J. Biol. Chem.
274,
34317-34326
|
| 26.
|
Jones, J. M.,
Nau, K.,
Geraghty, M. T.,
Erdmann, R.,
and Gould, S. J.
(1999)
J. Biol. Chem.
274,
9216-9223
|
| 27.
|
Watanabe, H.,
Shiratori, T.,
Shoji, H.,
Miyatake, S.,
Okazaki, Y.,
Ikuta, K.,
Sato, T.,
and Saito, T.
(1997)
Biochem. Biophys. Res. Commun.
238,
234-239
|
| 28.
|
Liu, L. X.,
Margottin, F., Le,
Gall, S.,
Schwartz, O.,
Selig, L.,
Benarous, R.,
and Benichou, S.
(1997)
J. Biol. Chem.
272,
13779-13785
|
| 29.
|
Shah, P. P.,
and Staple, E.
(1968)
Steroids
12,
571-575
|
| 30.
|
Prydz, K.,
Kase, B. F.,
Björkhem, I.,
and Pedersen, J. I.
(1986)
J. Lipid Res.
27,
622-628
|
| 31.
|
Bradford, M. M.
(1976)
Anal. Biochem.
72,
248-254
|
| 32.
|
Naggert, J.,
Narasimhan, M. L.,
DeVeaux, L.,
Cho, H.,
Randhawa, Z. I.,
Cronan, J. E.,
Green, B. N.,
and Smith, S.
(1991)
J. Biol. Chem.
266,
11044-11050
|
| 33.
|
Li, J.,
Derewenda, U.,
Dauter, Z.,
Smith, S.,
and Derewenda, Z. S.
(2000)
Nat. Struct. Biol.
7,
555-559
|
| 34.
|
Gould, S. J.,
Keller, G. A.,
Hosken, N.,
Wilkinson, J.,
and Subramani, S.
(1989)
J. Cell Biol.
108,
1657-1664
|
| 35.
|
Cohen, G. B.,
Rangan, V. S.,
Chen, B. K.,
Smith, S.,
and Baltimore, D.
(2000)
J. Biol. Chem.
275,
23097-23105
|
| 36.
|
Svensson, L. T.,
Wilcke, M.,
and Alexson, S. E. H.
(1995)
Eur. J. Biochem.
230,
813-820
|
| 37.
|
Lindquist, P. J. G.,
Svensson, L. T.,
and Alexson, S. E. H.
(1998)
Eur. J. Biochem.
251,
631-640
|
| 38.
|
Hunt, M. C.,
Yang, Y. Z.,
Eggertsen, G.,
Carneheim, C. M.,
Gåfvels, M.,
Einarsson, C.,
and Alexson, S. E. H.
(2000)
J. Biol. Chem.
37,
28947-28953
|
| 39.
|
Nemali, M. R.,
Usuda, N.,
Reddy, M. K.,
Oyasu, K.,
Hashimoto, T.,
Osumi, T.,
Rao, M. S.,
and Reddy, J. K.
(1988)
Cancer Res.
48,
5316-5324
|
| 40.
|
Jones, J. B.,
and Gould, S. J.
(2000)
Biochem. Biophys. Res. Commun.
275,
233-240
|
| 41.
|
Kestler, W. H.,
Ringler, D. J.,
Mori, K.,
Panicali, D. L.,
Shegal, P. K.,
Daniel, M. D.,
and Desrosiers, R. C.
(1991)
Cell
65,
651-662
|
| 42.
|
Liu, L. X.,
Heveker, N.,
Fackler, O. T.,
Arold, S., Le,
Gall, S.,
Janvier, K. P., B. M.,
Dumas, C.,
Schwartz, O.,
Benichou, S.,
and Benarous, R.
(2000)
J. Virol.
74,
5310-5319
|
| 43.
|
Van Broekhoven, A.,
Peeters, M. C.,
Debeer, L. J.,
and Mannaerts, G. P.
(1981)
Biochem. Biophys. Res. Commun.
100,
305-312
|
| 44.
|
Van Veldhoven, P. P.,
and Mannaerts, G. P.
(1986)
Biochem. Biophys. Res. Commun.
139,
1195-1201
|
| 45.
|
Horie, S.,
Isobe, M.,
and Suga, T.
(1986)
J. Biochem. (Tokyo)
99,
1345-1352
|
| 46.
|
Gasmi, L.,
and McLennan, A. G.
(2001)
Biochem. J.
357,
33-38
|
| 47.
|
Steinberg, S. J.,
Wang, S. J.,
Kim, D. G.,
Mihalik, S. J.,
and Watkins, P. A.
(1999)
Biochem. Biophys. Res. Commun.
257,
615-621
|
| 48.
|
Makishima, M.,
Okamoto, A. Y.,
Repa, J. J., Tu, H.,
Learned, R. M.,
Luk, A.,
Hull, M. V.,
Lustig, K. D.,
Mangelsdorf, D. J.,
and Shan, B.
(1999)
Science
284,
362-365
|
| 49.
|
Parks, D. J.,
Blanchard, S. G.,
Bledsoe, R. K.,
Chandra, G.,
Consler, T. G.,
Kliewer, S. A.,
Stimmel, J. B.,
Willson, T. M.,
Zavacki, A. M.,
Moore, D. D.,
and Lehmann, J. M.
(1999)
Science
284,
1285-1286
|
| 50.
|
Wang, H.,
Chen, J.,
Holoister, K.,
Sowers, L. C.,
and Forman, B. M.
(1999)
Mol. Cell
5,
543-553
|
| 51.
|
Grober, J.,
Zaghini, I.,
Fujii, H.,
Jones, S. A.,
Kliewer, S. A.,
Willson, T. M.,
Ono, T.,
and Besnard, P.
(1999)
J. Biol. Chem.
274,
29749-29754
|
| 52.
|
del Castillo-Olivares, A.,
and Gil, G.
(2000)
Nucleic Acids Res.
28,
3587-3593
|
| 53.
|
Chiang, J. Y.,
Kimmel, R.,
Weinberger, C.,
and Stroup, D.
(2000)
J. Biol. Chem.
275,
10918-10924
|
| 54.
|
Hertz, R.,
Magenheim, J.,
Berman, I.,
and Bar-Tana, J.
(1998)
Nature
392,
512-516
|
| 55.
|
Hertz, R.,
Sheena, V.,
Kalderon, B.,
Berman, I.,
and Bar-Tana, J.
(2001)
Biochem. Pharmacol.
61,
1057-1062
|
| 56.
|
Thompson, S. L.,
and Krisans, S. K.
(1990)
J. Biol. Chem.
265,
5731-5735
|
| 57.
|
Olivier, L. M.,
Kovacs, W.,
Masuda, K.,
Keller, G. A.,
and Krisans, S. K.
(2000)
J. Lipid Res.
41,
1921-1935
|
| 58.
|
Keller, G. A.,
Barton, M. C.,
Shapiro, D. J.,
and Singer, S. J.
(1985)
Proc. Natl. Acad. Sci. U. S. A.
82,
770-774
|
| 59.
|
Keller, G. A.,
Pazirandeh, M.,
and Krisans, S.
(1986)
J. Cell Biol.
103,
875-886
|
| 60.
|
Rusnak, N.,
and Krisans, S. K.
(1987)
Biochem. Biophys. Res. Commun.
148,
890-895
|
| 61.
|
Brass, E. P.
(1994)
Chem. Biol. Interact.
90,
203-214
|
| 62.
|
Leighton, F.,
Bergseth, S.,
Rørtveit, T.,
Christiansen, E. N.,
and Bremer, J.
(1989)
J. Biol. Chem.
264,
10347-10350
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S.-J. Reilly, V. Tillander, R. Ofman, S. E.H. Alexson, and M. C. Hunt
The Nudix Hydrolase 7 is an Acyl-CoA Diphosphatase Involved in Regulating Peroxisomal Coenzyme A Homeostasis
J. Biochem.,
November 1, 2008;
144(5):
655 - 663.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. K. Westin, M. C. Hunt, and S. E. H. Alexson
Peroxisomes Contain a Specific Phytanoyl-CoA/Pristanoyl-CoA Thioesterase Acting as a Novel Auxiliary Enzyme in {alpha}- and beta-Oxidation of Methyl-branched Fatty Acids in Mouse
J. Biol. Chem.,
September 14, 2007;
282(37):
26707 - 26716.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Islinger, G. H. Luers, K. W. Li, M. Loos, and A. Volkl
Rat Liver Peroxisomes after Fibrate Treatment: A SURVEY USING QUANTITATIVE MASS SPECTROMETRY
J. Biol. Chem.,
August 10, 2007;
282(32):
23055 - 23069.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S.-J. Reilly, E. M. O'Shea, U. Andersson, J. O'Byrne, S. E. H. Alexson, and M. C. Hunt
A peroxisomal acyltransferase in mouse identifies a novel pathway for taurine conjugation of fatty acids
FASEB J,
January 1, 2007;
21(1):
99 - 107.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. R. Boverhof, L. D. Burgoon, C. Tashiro, B. Sharratt, B. Chittim, J. R. Harkema, D. L. Mendrick, and T. R. Zacharewski
Comparative Toxicogenomic Analysis of the Hepatotoxic Effects of TCDD in Sprague Dawley Rats and C57BL/6 Mice
Toxicol. Sci.,
December 1, 2006;
94(2):
398 - 416.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. C. Hunt, A. Rautanen, M. A. K. Westin, L. T. Svensson, and S. E. H. Alexson
Analysis of the mouse and human acyl-CoA thioesterase (ACOT) gene clusters shows that convergent, functional evolution results in a reduced number of human peroxisomal ACOTs
FASEB J,
September 1, 2006;
20(11):
1855 - 1864.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. M. Jenkins, W. Yan, D. J. Mancuso, and R. W. Gross
Highly Selective Hydrolysis of Fatty Acyl-CoAs by Calcium-independent Phospholipase A2beta: ENZYME AUTOACYLATION AND ACYL-CoA-MEDIATED REVERSAL OF CALMODULIN INHIBITION OF PHOSPHOLIPASE A2 ACTIVITY
J. Biol. Chem.,
June 9, 2006;
281(23):
15615 - 15624.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Maeda, S. Delessert, S. Hasegawa, Y. Seto, S. Zuber, and Y. Poirier
The Peroxisomal Acyl-CoA Thioesterase Pte1p from Saccharomyces cerevisiae Is Required for Efficient Degradation of Short Straight Chain and Branched Chain Fatty Acids
J. Biol. Chem.,
April 28, 2006;
281(17):
11729 - 11735.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Song, Z. Zhuang, L. Finci, D. Dunaway-Mariano, R. Kniewel, J. A. Buglino, V. Solorzano, J. Wu, and C. D. Lima
Structure, Function, and Mechanism of the Phenylacetate Pathway Hot Dog-fold Thioesterase PaaI
J. Biol. Chem.,
April 21, 2006;
281(16):
11028 - 11038.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. K. Westin, M. C. Hunt, and S. E. H. Alexson
The Identification of a Succinyl-CoA Thioesterase Suggests a Novel Pathway for Succinate Production in Peroxisomes
J. Biol. Chem.,
November 18, 2005;
280(46):
38125 - 38132.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. C. Hunt, J. Yamada, L. J. Maltais, M. W. Wright, E. J. Podesta, and S. E. H. Alexson
A revised nomenclature for mammalian acyl-CoA thioesterases/hydrolases
J. Lipid Res.,
September 1, 2005;
46(9):
2029 - 2032.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Bian, T. Kasumov, K. R. Thomas, K. A. Jobbins, F. David, P. E. Minkler, C. L. Hoppel, and H. Brunengraber
Peroxisomal and Mitochondrial Oxidation of Fatty Acids in the Heart, Assessed from the 13C Labeling of Malonyl-CoA and the Acetyl Moiety of Citrate
J. Biol. Chem.,
March 11, 2005;
280(10):
9265 - 9271.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Stavinoha, J. W. RaySpellicy, M. F. Essop, C. Graveleau, E. D. Abel, M. L. Hart-Sailors, H. J. Mersmann, M. S. Bray, and M. E. Young
Evidence for mitochondrial thioesterase 1 as a peroxisome proliferator-activated receptor-{alpha}-regulated gene in cardiac and skeletal muscle
Am J Physiol Endocrinol Metab,
November 1, 2004;
287(5):
E888 - E895.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Reumann, C. Ma, S. Lemke, and L. Babujee
AraPerox. A Database of Putative Arabidopsis Proteins from Plant Peroxisomes
Plant Physiology,
September 1, 2004;
136(1):
2587 - 2608.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Solaas, B. F. Kase, V. Pham, K. Bamberg, M. C. Hunt, and S. E. H. Alexson
Differential regulation of cytosolic and peroxisomal bile acid amidation by PPAR{alpha} activation favors the formation of unconjugated bile acids
J. Lipid Res.,
June 1, 2004;
45(6):
1051 - 1060.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. K. Westin, S. E. H. Alexson, and M. C. Hunt
Molecular Cloning and Characterization of Two Mouse Peroxisome Proliferator-activated Receptor {alpha} (PPAR{alpha})-regulated Peroxisomal Acyl-CoA Thioesterases
J. Biol. Chem.,
May 21, 2004;
279(21):
21841 - 21848.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Bauer, A. C. Hamm, M. Bonaus, A. Jacob, J. Jaekel, H. Schorle, M. J. Pankratz, and J. D. Katzenberger
Starvation response in mouse liver shows strong correlation with life-span-prolonging processes
Physiol Genomics,
April 13, 2004;
17(2):
230 - 244.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. B. Tilton, J. M. Shockey, and J. Browse
Biochemical and Molecular Characterization of ACH2, an Acyl-CoA Thioesterase from Arabidopsis thaliana
J. Biol. Chem.,
February 27, 2004;
279(9):
7487 - 7494.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Jia, C. Qi, Z. Zhang, T. Hashimoto, M. S. Rao, S. Huyghe, Y. Suzuki, P. P. Van Veldhoven, M. Baes, and J. K. Reddy
Overexpression of Peroxisome Proliferator-activated Receptor-{alpha} (PPAR{alpha})-regulated Genes in Liver in the Absence of Peroxisome Proliferation in Mice Deficient in both L- and D-Forms of Enoyl-CoA Hydratase/Dehydrogenase Enzymes of Peroxisomal {beta}-Oxidation System
J. Biol. Chem.,
November 21, 2003;
278(47):
47232 - 47239.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. O'Byrne, M. C. Hunt, D. K. Rai, M. Saeki, and S. E. H. Alexson
The Human Bile Acid-CoA:Amino Acid N-Acyltransferase Functions in the Conjugation of Fatty Acids to Glycine
J. Biol. Chem.,
September 5, 2003;
278(36):
34237 - 34244.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. K. Sfakianos, L. Wilson, M. Sakalian, C. N. Falany, and S. Barnes
Conserved Residues in the Putative Catalytic Triad of Human Bile Acid Coenzyme A:Amino Acid N-Acyltransferase
J. Biol. Chem.,
November 27, 2002;
277(49):
47270 - 47275.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Huhtinen, J. O'Byrne, P. J. G. Lindquist, J. A. Contreras, and S. E. H. Alexson
The Peroxisome Proliferator-induced Cytosolic Type I Acyl-CoA Thioesterase (CTE-I) Is a Serine-Histidine-Aspartic Acid alpha /beta Hydrolase
J. Biol. Chem.,
January 25, 2002;
277(5):
3424 - 3432.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|